Overcoming immune suppression in the tumor microenvironment

Implications for multi-modal therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Effective immunotherapy, whether by checkpoint blockade, vaccines or adoptive cell therapy, is limited in most patients by a fundamental barrier: the immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunotherapy has focused on downstream checkpoints that regulate activated T cells, or on vaccination and T cell adoptive transfer to expand the T cell pool. Relatively less attention has been given to regulatory pathways that govern cross-presentation and response to endogenous tumor antigens. But these “upstream” pathways become particularly important in settings where immunotherapy is combined with standard-of-care chemotherapy or radiation therapy, both of which release a wave of tumor antigens. The choice of whether to treat these antigens as tolerizing or immunizing is fundamental to generating an effective immune response against the tumor. In this chapter we consider immunosuppressive mechanisms in the tumor microenvironment from the perspective of factors that that may impact the response to antigens from dying tumor cells.

Original languageEnglish (US)
Title of host publicationImmunotherapy for Pediatric Malignancies
PublisherSpringer International Publishing
Pages13-38
Number of pages26
ISBN (Electronic)9783319434865
ISBN (Print)9783319434841
DOIs
StatePublished - Jan 1 2017

Fingerprint

Tumor Microenvironment
T-Lymphocytes
Neoplasm Antigens
Immunotherapy
Immunosuppressive Agents
Cross-Priming
Therapeutics
Adoptive Transfer
Antigen-Presenting Cells
Standard of Care
Cell- and Tissue-Based Therapy
Vaccination
Radiotherapy
Vaccines
Antigens
Drug Therapy
Neoplasms

Keywords

  • Checkpoint
  • Chemotherapy
  • IDO
  • Immunotherapy
  • Indoleamine 2,3-dioxygenase
  • Radiation
  • Tolerance
  • Tumor
  • Tumor microenvironment

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Overcoming immune suppression in the tumor microenvironment : Implications for multi-modal therapy. / Johnson, Theodore Samuel; Munn, David H.

Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. p. 13-38.

Research output: Chapter in Book/Report/Conference proceedingChapter

Johnson, Theodore Samuel ; Munn, David H. / Overcoming immune suppression in the tumor microenvironment : Implications for multi-modal therapy. Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. pp. 13-38
@inbook{9c3a6873b11c4150bfbc42f45764aea2,
title = "Overcoming immune suppression in the tumor microenvironment: Implications for multi-modal therapy",
abstract = "Effective immunotherapy, whether by checkpoint blockade, vaccines or adoptive cell therapy, is limited in most patients by a fundamental barrier: the immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunotherapy has focused on downstream checkpoints that regulate activated T cells, or on vaccination and T cell adoptive transfer to expand the T cell pool. Relatively less attention has been given to regulatory pathways that govern cross-presentation and response to endogenous tumor antigens. But these “upstream” pathways become particularly important in settings where immunotherapy is combined with standard-of-care chemotherapy or radiation therapy, both of which release a wave of tumor antigens. The choice of whether to treat these antigens as tolerizing or immunizing is fundamental to generating an effective immune response against the tumor. In this chapter we consider immunosuppressive mechanisms in the tumor microenvironment from the perspective of factors that that may impact the response to antigens from dying tumor cells.",
keywords = "Checkpoint, Chemotherapy, IDO, Immunotherapy, Indoleamine 2,3-dioxygenase, Radiation, Tolerance, Tumor, Tumor microenvironment",
author = "Johnson, {Theodore Samuel} and Munn, {David H}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43486-5_2",
language = "English (US)",
isbn = "9783319434841",
pages = "13--38",
booktitle = "Immunotherapy for Pediatric Malignancies",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Overcoming immune suppression in the tumor microenvironment

T2 - Implications for multi-modal therapy

AU - Johnson, Theodore Samuel

AU - Munn, David H

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Effective immunotherapy, whether by checkpoint blockade, vaccines or adoptive cell therapy, is limited in most patients by a fundamental barrier: the immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunotherapy has focused on downstream checkpoints that regulate activated T cells, or on vaccination and T cell adoptive transfer to expand the T cell pool. Relatively less attention has been given to regulatory pathways that govern cross-presentation and response to endogenous tumor antigens. But these “upstream” pathways become particularly important in settings where immunotherapy is combined with standard-of-care chemotherapy or radiation therapy, both of which release a wave of tumor antigens. The choice of whether to treat these antigens as tolerizing or immunizing is fundamental to generating an effective immune response against the tumor. In this chapter we consider immunosuppressive mechanisms in the tumor microenvironment from the perspective of factors that that may impact the response to antigens from dying tumor cells.

AB - Effective immunotherapy, whether by checkpoint blockade, vaccines or adoptive cell therapy, is limited in most patients by a fundamental barrier: the immunosuppressive tumor microenvironment. This problem is more than just the suppression of effector T cells, but also includes profound defects in the inflammatory milieu and immunogenic antigen-presenting cells that are required to drive T cell activation. To date, much of the field of immunotherapy has focused on downstream checkpoints that regulate activated T cells, or on vaccination and T cell adoptive transfer to expand the T cell pool. Relatively less attention has been given to regulatory pathways that govern cross-presentation and response to endogenous tumor antigens. But these “upstream” pathways become particularly important in settings where immunotherapy is combined with standard-of-care chemotherapy or radiation therapy, both of which release a wave of tumor antigens. The choice of whether to treat these antigens as tolerizing or immunizing is fundamental to generating an effective immune response against the tumor. In this chapter we consider immunosuppressive mechanisms in the tumor microenvironment from the perspective of factors that that may impact the response to antigens from dying tumor cells.

KW - Checkpoint

KW - Chemotherapy

KW - IDO

KW - Immunotherapy

KW - Indoleamine 2,3-dioxygenase

KW - Radiation

KW - Tolerance

KW - Tumor

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85042614319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042614319&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43486-5_2

DO - 10.1007/978-3-319-43486-5_2

M3 - Chapter

SN - 9783319434841

SP - 13

EP - 38

BT - Immunotherapy for Pediatric Malignancies

PB - Springer International Publishing

ER -